This article explains, in educational terms, intraosseous spinal tumor ablation — how the technology works and where it fits. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ.
Intraosseous Ablation for Spinal Tumors
Intraosseous ablation delivers energy directly into bone to target vertebral or spinal tumors, an environment that differs from soft tissue because of the dense, mineralized matrix involved. Radiofrequency energy can be used to coagulate tumor tissue within the vertebral body, and it is sometimes combined with cement augmentation as decided by the treating team. INVAMED's Fusion Intraosseous Radiofrequency Ablation System for Spinal Tumors is positioned specifically for intraosseous RF delivery in vertebral and spinal tumor ablation. Whether intraosseous ablation is appropriate, and how it fits within a broader oncologic and pain-management plan, is determined by the clinician.
Design and Technical Notes
INVAMED groups its ablation portfolio by the energy modality and anatomical target, offering radiofrequency platforms for soft tissue and bone as well as an intracavitary hypothermia set. Each device is intended for use by trained clinicians under appropriate image guidance and per the instructions for use (IFU). For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning. Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions.
Key Considerations
- Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions.
- Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
- Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone.
Frequently Asked Questions
Does ablation replace surgery?
Not necessarily; ablation is a local, minimally invasive option that may be considered instead of or alongside surgery in appropriately selected patients, and the decision is made within a multidisciplinary team.
Who decides whether ablation is appropriate?
A qualified clinical team decides based on tumor characteristics and patient factors; this article is educational and not a treatment recommendation.
How is microwave ablation different from radiofrequency ablation?
Both are heat-based, but microwave ablation is often described as heating tissue faster and being less affected by the heat-sink effect near vessels, while RFA has a particularly deep evidence base; the choice is made by the clinician.
About INVAMED
INVAMED is a medical device manufacturer headquartered in Ankara, Turkey, founded in 2005. INVAMED states it maintains a growing portfolio of international patents across its device range.
Clinical and Technical Context
Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone. INVAMED's Peta Radiofrequency Ablation (RFA) System is a generator-based ablation platform offered in variants for soft-tissue and liver tumor ablation as well as nerve (pain) ablation, and the multi-application ThermoEdge RFA Platform is positioned for liver and kidney tissue resection, cysts, and endometrial ablation. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. All INVAMED ablation devices are intended for use by trained clinicians under appropriate image guidance and in accordance with the IFU.
Related on INVAMED
- Oncology Ablation — product category
- Cryoablation for Renal Tumors: Technology, Uses and Considerations
- Microwave Ablation (MWA) Systems Explained — A Technical Guide
- ThermoEdge RFA Platform — Technical Overview
Important Disclaimer
The information here is provided for educational purposes and to describe device technology; it is not a substitute for professional medical advice, diagnosis, or treatment. Only a licensed healthcare provider can determine whether a given procedure or device is appropriate for a specific patient. INVAMED products are restricted to use by qualified professionals following the official IFU. Regulatory clearance and labeling differ between regions, and not all products or indications are available in every market.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.